Novo says it will offer weight-loss pill via telehealth, Bloomberg reports
Hims & Hers slipped after Novo Nordisk’s US head, David Moore, told Bloomberg that the company plans to sell its upcoming weight-loss pill through its current telehealth partners.
The company’s weight-loss pill recently reported encouraging results in a late-stage trial.
Novo currently has partnerships with Hims competitors like Ro and Weight Watchers. Hims had a deal with Novo earlier this year, which blew up epically in less than two months.
Ro — Hims’ biggest competitor — is currently integrated with Novo’s cash pay direct-to-consumer pharmacy, which allows it to offer its users branded Ozempic or Wegovy at a cheaper price. Once Novo’s much-awaited weight-loss pill hits the market, Moore told Bloomberg, it will also be offered on those platforms.
Ro — Hims’ biggest competitor — is currently integrated with Novo’s cash pay direct-to-consumer pharmacy, which allows it to offer its users branded Ozempic or Wegovy at a cheaper price. Once Novo’s much-awaited weight-loss pill hits the market, Moore told Bloomberg, it will also be offered on those platforms.
